Manatt Logo
Menu
  • Industries
    • Manatt Digital and Technology
    • Manatt Energy and Environment
    • Manatt Entertainment
    • Manatt Financial Services
    • Manatt Health
    • Manatt Real Estate
    • Manatt Retail and Consumer Products
  • Services
    • Business Strategy and Consulting
      • Artificial Intelligence
      • Digital and Technology Consulting
      • Digital Health
      • Education
      • Manatt Health
      • Manatt Housing Solutions
      • Manatt Real Estate Advisors
      • Manatt's Recovery Team
      • Name Image Likeness (NIL) in College Athletics
    • Corporate and Finance
      • Blockchain and Cryptocurrency
      • Cannabis and CBD
      • Capital Markets
      • Digital and Technology Transactions
      • Distressed Assets
      • Education
      • Estate Planning and Personal Representation
      • Executive Compensation and Employee Benefits
      • Financial Services Transactions
      • Fintech
      • Games and Esports
      • Global Payments
      • Health Care Transactions
      • Hospitality and Leisure
      • Impact Investing and Community Development
      • Manatt Leasing
      • Mergers and Acquisitions
      • Music
      • Name Image Likeness (NIL) in College Athletics
      • Private Equity and Buyout
      • Real Estate Transactions and Finance
      • Special Purpose Acquisition Companies (SPACs)
      • Tax
      • Venture Capital / Emerging Companies
    • Government and Regulatory
      • Advertising, Marketing and Media
      • California State Government and Regulatory Policy and Government Contracts
      • Digital Health
      • Environment
      • Federal Government Affairs and Public Policy
      • Government Litigation and Administrative Law
      • Insurance
      • Investigations, Compliance and White Collar Defense
      • Land Use
      • Los Angeles Government and Land Use
      • Manatt Energy and Environment
      • Manatt Health
      • National Advertising Division
      • New York City Government, Policy and Government Contracts
      • New York State Government, Regulatory Policy and Government Contracts
    • Litigation
      • Advertising Litigation
      • Antitrust and Competition
      • Appellate
      • Artificial Intelligence
      • Bankruptcy
      • Capabilities to Serve Clients During COVID-19
      • Class Actions
      • Consumer Protection
      • Digital Media Litigation
      • Employment and Labor
      • Entertainment Litigation
      • Environmental Litigation
      • False Claims Act
      • Financial Services Litigation and Enforcement
      • Games and Esports
      • Government Litigation and Administrative Law
      • Health Care Litigation
      • Insurance
      • Intellectual Property Protection and Enforcement
      • Investigations, Compliance and White Collar Defense
      • Music
      • National Advertising Division
      • Privacy and Data Security
      • Private Wealth and Fiduciary Disputes
      • Real Estate Litigation
      • TCPA Compliance and Class Action Defense
      • Technology and Intellectual Property Litigation
      • Trademark and Copyright Litigation
      • Unmanned Aircraft
  • People
  • Insights
    • News
    • Articles
    • Webinars
    • Podcasts
    • Events and Engagements
    • Newsletters
    • White Papers
  • Hot Topics
    • Federal Trade Commission
    • Artificial Intelligence
    • No Surprises Act
    • Women's Reproductive Health
    • Metaverse
    • Long-Term Care/Long-Term Services and Supports
    • Behavioral Health
    • Drivers of Health
    • Children's Health
    • COVID-19
    • State Privacy Legislative Updates
    • Medicaid Managed Care
  • About Us
    • About Manatt
    • Contact Us
    • Management
    • Diversity
    • Women's Initiative
    • Pro Bono
    • Capabilities to Serve Clients During COVID-19
    • Manatt for Entrepreneurs
    • Manatt on Health
  • Careers
  • Offices
  • Manatt on Health
  • Manatt for Entrepreneurs
  • Client Login
Manatt Logo
  • Industries
    • Manatt Digital and Technology
    • Manatt Energy and Environment
    • Manatt Entertainment
    • Manatt Financial Services
    • Manatt Health
    • Manatt Real Estate
    • Manatt Retail and Consumer Products
  • Services
    • Business Strategy and Consulting
      • Artificial Intelligence
      • Digital and Technology Consulting
      • Digital Health
      • Education
      • Manatt Health
      • Manatt Housing Solutions
      • Manatt Real Estate Advisors
      • Manatt's Recovery Team
      • Name Image Likeness (NIL) in College Athletics
    • Corporate and Finance
      • Blockchain and Cryptocurrency
      • Cannabis and CBD
      • Capital Markets
      • Digital and Technology Transactions
      • Distressed Assets
      • Education
      • Estate Planning and Personal Representation
      • Executive Compensation and Employee Benefits
      • Financial Services Transactions
      • Fintech
      • Games and Esports
      • Global Payments
      • Health Care Transactions
      • Hospitality and Leisure
      • Impact Investing and Community Development
      • Manatt Leasing
      • Mergers and Acquisitions
      • Music
      • Name Image Likeness (NIL) in College Athletics
      • Private Equity and Buyout
      • Real Estate Transactions and Finance
      • Special Purpose Acquisition Companies (SPACs)
      • Tax
      • Venture Capital / Emerging Companies
    • Government and Regulatory
      • Advertising, Marketing and Media
      • California State Government and Regulatory Policy and Government Contracts
      • Digital Health
      • Environment
      • Federal Government Affairs and Public Policy
      • Government Litigation and Administrative Law
      • Insurance
      • Investigations, Compliance and White Collar Defense
      • Land Use
      • Los Angeles Government and Land Use
      • Manatt Energy and Environment
      • Manatt Health
      • National Advertising Division
      • New York City Government, Policy and Government Contracts
      • New York State Government, Regulatory Policy and Government Contracts
    • Litigation
      • Advertising Litigation
      • Antitrust and Competition
      • Appellate
      • Artificial Intelligence
      • Bankruptcy
      • Capabilities to Serve Clients During COVID-19
      • Class Actions
      • Consumer Protection
      • Digital Media Litigation
      • Employment and Labor
      • Entertainment Litigation
      • Environmental Litigation
      • False Claims Act
      • Financial Services Litigation and Enforcement
      • Games and Esports
      • Government Litigation and Administrative Law
      • Health Care Litigation
      • Insurance
      • Intellectual Property Protection and Enforcement
      • Investigations, Compliance and White Collar Defense
      • Music
      • National Advertising Division
      • Privacy and Data Security
      • Private Wealth and Fiduciary Disputes
      • Real Estate Litigation
      • TCPA Compliance and Class Action Defense
      • Technology and Intellectual Property Litigation
      • Trademark and Copyright Litigation
      • Unmanned Aircraft
  • People
  • Insights
    • News
    • Articles
    • Webinars
    • Podcasts
    • Events and Engagements
    • Newsletters
    • White Papers
  • Hot Topics
    • Federal Trade Commission
    • Artificial Intelligence
    • No Surprises Act
    • Women's Reproductive Health
    • Metaverse
    • Long-Term Care/Long-Term Services and Supports
    • Behavioral Health
    • Drivers of Health
    • Children's Health
    • COVID-19
    • State Privacy Legislative Updates
    • Medicaid Managed Care
  • About Us
    • About Manatt
    • Contact Us
    • Management
    • Diversity
    • Women's Initiative
    • Pro Bono
    • Capabilities to Serve Clients During COVID-19
    • Manatt for Entrepreneurs
    • Manatt on Health
  • Careers
  • Offices
  • Manatt on Health
  • Manatt for Entrepreneurs
  • Client Login
  • Home
  • People
  • Rachel L. Sher
Language:
  • English
    • English
    • Spanish
    • Portuguese
Share:

Rachel L. Sher

Partner

Manatt Health
Contact
  • rsher@manatt.com
  • Phone: 202.624.3302
  • Download vCard
  • Washington, D.C.
Bar Admissions
  • Washington, D.C.

Education
  • The George Washington University – School of Public Health, M.P.H., 2004

    University of Florida – Levin College of Law, J.D., 2000

    Duke University, B.A., 1995

Industries
  • Artificial Intelligence
  • Digital Health
  • Manatt Health

Show Full Bio

  • Profile
  • Speaking Engagements
  • Memberships
  • Publications
Profile

Profile

Rachel Sher is a prominent Food and Drug Administration (FDA) regulatory leader with sophisticated experience in policy and legislative strategy who helps support life sciences companies as they navigate the broader FDA regulatory process across all stages of a product’s life cycle.

With nearly 20 years of experience in the health policy space, specifically in the pharmaceutical and medical device arenas, Rachel provides a multifaceted approach to solving issues clients face in the medical products area, advising on compliance with the many complex legal and regulatory requirements governing successful product review, launch and marketing. She also helps clients facing serious challenges in this process consider a subsequent or corresponding legislative strategy to advance any additional needs surrounding their development programs.

Rachel previously served as the Vice President of Policy and Regulatory Affairs for the National Organization for Rare Disorders (NORD), where she led its federal policy and regulatory work with respect to the FDA and other federal agencies, as well as on Capitol Hill and in the states. Sher also served as Deputy General Counsel at the Association for Accessible Medicines (AAM), where she helped oversee the AAM’s legal affairs, including the review of advocacy and policy statements. Prior to her time at AAM, Sher worked in the Commissioner’s Office at the FDA where she led the agency’s engagement on the 21st Century Cures Act legislative process, which involved working directly with FDA leadership and medical product centers to give strategic advice and guidance. Prior to heading to the FDA, Rachel spent ten years on Capitol Hill working as FDA Counsel for the Committee on Energy and Commerce, where she had the rare opportunity to oversee the entire FDA-related portfolio, drafting and negotiating all major FDA legislation enacted during her tenure.

Speaking Engagements

Speaking Engagements

Panelist, “Rare Disease Drug Development: Present Problems and Solutions,” Food and Drug Law Institute 2023 Annual Conference, May 17, 2023.

Speaker, “The FDCA Impact of Dobbs,” 2022 Enforcement, Litigation, and Compliance Conference: For the Drug, Device, Food, and Tobacco Industries, Food and Drug Law Institute, December 7, 2022.

Moderator, “Updates in Orphan Drug Regulation and Litigation,” Food and Drug Law Institute, June 15, 2022.

Speaker, “Breaking New Ground: Innovations in Alzheimer’s Research,” The Hill, March 2, 2022.

Panelist, Strategies to Support Rare Disease Product Development During COVID-19, Rare Disease Day 2021, FDA, March 5, 2021.

Speaker, Rare Disease Day, National Institutes of Health (NIH), March 1, 2021.

Speaker, Rare Disease Policy Webinar, MDA Advocacy Institute, February 25, 2021.

Moderator, COVID-19 Vaccines Update: FDA and CDC Leaders Address the Rare Disease Community, NORD, January 15, 2021.

Moderator, Perspectives From The Hill: The Year to Date and What’s Ahead, Rare Diseases and Orphan Products Breakthrough Summit, NORD, October 8, 2020.

Speaker, Webinar On Resilience Approach Towards Rare Disease Policy In India, People to People Health Foundation (PPHF) and GRID Council, August 4, 2020.

Speaker, Public Meeting on the Reauthorization of the Prescription Drug User Fee Act (PDUFA), FDA, July 23, 2020.

Speaker, FDLI Annual Conference: Exploring Advanced Topics in Food and Drug Law, Food and Drug Law Institute, May 2, 2019.

Panelist, Tissue Agnostic Therapies: Regulatory Considerations for Orphan Drug Designation; Public Workshop, FDA, May 9, 2018.

Panelist, Updating Outdated Product Labels, Friends of Cancer Research Annual Meeting, Friends of Cancer Research, November 15, 2017.

Panelist, Market Access, Market Success, 2017 Leading on Biosimilars Conference, AAM, September 12, 2017.

Panelist, Developing a National Registry of Pharmacologic and Biologic Clinical Trials, Committee on Clinical Trial Registries, Board on Health Sciences Policy, Institute of Medicine, June 27, 2005.

Memberships

Memberships

Admitted to practice in the District of Columbia

Publications

Publications

Co-author, “Achieving Diversity in Clinical Trials: Expanding Hospital Capacity to Offer Clinical Trials in the Community,” a white paper prepared for Manatt Health, August 2023.

Quoted, “Fifth Circuit Mifepristone Ruling May Temporarily Halt Pharmacy Dispensing, Generic Approval,” Pink Sheet, April 13, 2023.

Quoted, “Abortion case could spell trouble for FDA,” National Journal, April 11, 2023.

Quoted, “Can Courts And States Override FDA’s Drug Regulatory Authority?,” Pink Sheet, February 27, 2023.

Quoted, “Abortion lawsuits place federal drug authority in the crosshairs,” National Journal, February 9, 2023.

Quoted, “FDA restores orphan-exclusivity system after 18-month stall in wake of legal feud,” MM+M, January 31, 2023.

Quoted, “Medtech regulation outlook in 2023: Faster approvals among priorities as AI moves to fore,” MedTech Dive, January 26, 2023.

Quoted,” FDA Refuses to Apply Catalyst Decision to All Orphan Drugs,” Bloomberg Law, January 23, 2023.

Quoted, “Diversity in Clinical Trials at FDA Gets a Boost From New Law,” Bloomberg Law, January 19, 2023.

Quoted, “What Will FDA Do In Battle Over Medication Abortion Access?,” Pink Sheet, December 12, 2022.

Quoted, “US OTC Oral Contraceptive Access Could Mirror ‘Patchwork’ Of States’ Limits On Abortion Drug,” Pharma Intelligence, December 12, 2022.

Quoted, “As deadline for FDA user fees bill nears, Congress weighs continuing resolution,” MedTech Dive, September 22, 2022.

Quoted, “The Hottest Topics For Health Attys In 2022's Homestretch,” Law360, September 2, 2022.

Quoted, “Congress Might Add ‘Clean’ FDA User Fee Bill To Stopgap Funding To Buy Time,” InsideHealthPolicy, September 1, 2022.

Quoted, “6 questions for the medtech industry if Congress doesn’t reauthorize FDA user fees on time,” MedTech Dive, August 3, 2022.

Quoted,” Senate unveils user fee reauthorization draft, leaves out accelerated approval reform,” MM+M, May 19, 2022.

Quoted, “Woodcock To Chair FDA’s Cannabis Council As It Implements Data Plan,” InsideHealthPolicy, May 3, 2022.

Quoted, “Accelerated Approval: How The Aduhelm Probes Will, And Won’t, Impact The Debate,” Pink Sheet, April 11, 2022.

Featured, “Health Care Appears Top Priority in DC as Law Firms Deepen Rosters,” The National Law Journal, January 20, 2022.

Rachel in the News

  • 04.12.23

    Sher Quoted on Potential Challenges to FDA’s Drug Approval Authority

    Rachel Sher was quoted in National Journal and HBW Insight on how a recent Fifth Circuit decision surrounding the availability of a medication abor...

  • 03.15.23

    Manatt Supports Launch of NCATS Alliance Alongside Leading Health ...

    Manatt, Phelps & Phillips, LLP, a multidisciplinary, integrated professional services firm, is proud to support the establishment of the NCATS ...

  • 02.27.23

    Sher Quoted in Pink Sheet on Recent Challenges to FDA’s Drug Approval ...

    Rachel Sher was quoted in Pink Sheet about the recent lawsuits challenging the Food and Drug Administration’s (FDA) authority to approve and ...

  • 01.31.23

    Sher Quoted in MM+M on FDA Orphan Drug Exclusivity System

    Manatt Health Partner Rachel Sher was quoted in an MM+M article about the Food and Drug Administration’s (FDA) recent action that has ...

Show More

Rachel's Articles

  • 09.25.23

    Anti-Obesity Medications as Medicare Part D Drugs: Legal and Health ...

    Commissioned by Pfizer Inc. Obesity is a complex, multifactorial disease that has serious health consequences, affects millions of Americans ...



  • 09.07.23

    Achieving Diversity in Clinical Trials: Expanding Hospital Capacity ...

    The inclusion of racial and ethnic groups in clinical trials has been a national priority for decades, but progress toward that end has been ...



Rachel's Newsletters

  • 08.21.23

    5th Circuit Rejects FDA Actions Expanding Access to Medication ...

    On Wednesday, August 16, the Fifth Circuit Court of Appeals issued a ruling upholding parts of a Texas district court’s decision that would, if ...

  • 06.28.23

    FDA Issues New Draft Guidance on Clinical Testing of Psychedelic Drugs

    On June 23, 2023, FDA issued a first-of-its-kind draft guidance for sponsors of studies of psychedelic drugs. The guidance arrived just as the ...

  • 04.14.23

    Federal Courts Divided: Medication Abortion and the Uncertain Future ...

    Less than one year after the Supreme Court overturned the federal constitutional right to abortion in Dobbs v. Jackson Women’s Health ...

  • 03.23.23

    FDA Announces the Discontinuation of Certain COVID-19-Related ...

    The United States Food and Drug Administration published a notice in the Federal Register on March 13, 2023, addressing the agency’s various ...

Show More


Rachel's Events and Webinars

  • 10.03.23

    Navigating the Mainstreaming of Psychedelic Drugs in the United ...

    In recent years, an unprecedented level of interest in the promise of psychedelics has taken hold. In the United States, many types of psychedelics ...



  • 07.11.23

    Abortion Access Post-Dobbs: Confusion, Confrontation and the Courts

    One year ago, the Supreme Court overturned Roe v. Wade and the decades of decisions that had followed it, resting authority to regulate or ...



  • 03.15.23

    The NCATS Alliance: Speeding the Process of Bringing New Treatments ...

    Featuring Francis Collins, M.D., Ph.D., Senior Advisor to President Biden and Former Director of the National Institutes of Health, and Joni Rutter, ...



  • 02.01.23

    Reimagining Medicine: Can Policy Keep Pace With Scientific Advances?

    Speakers From AbbVie, National Institutes of Health, National Organization for Rare Disorders, NYU Grossman School of Medicine and Verily Share ...



Show More
manatt-black

ATTORNEY ADVERTISING

pursuant to New York DR 2-101(f)

© 2023 Manatt, Phelps & Phillips, LLP.

All rights reserved 

 

  • Services
  • People
  • Insights
  • About Us
  • Careers
  • Offices & Contacts
  • Disclaimer
  • Privacy Statement

Share This Page

Your Information
Recipient's Information